Incidênciado câncer do colo do útero no estado de goiás de 2006 a 2014

Abstract

INTRODUCTION: Human Papilloma Virus (HPV) is a sexually transmitted infection (STI) that affects both sexes in the sexually active world, common in the female population. Causes mucosal injury. The columnar escutcheon junction (JEC) is an area with transformation potential (metalepsia) that is vulnerable to neoplasia caused by HPV. They are asymptomatic initially, it is transient, in persistence it evolves to cervical cancer (CCU). The HPV virus expresses oncogenic proteins at E6 and E7 inactive and destroys p53 that stops abnormalities in the cellular DNA, is still deactivates the telomerase responsible for determining amount of normal cell division, which happens to divide eternally (cell immortalization) in a way progressive, accelerated and rapid proliferation with infiltrative and increasingly differentiated. OBJECTIVES:To determine incidence in the number of women with cervical cancer in the state of Goiás, from 2006 to 2014; identify and describe types of lesions with higher incidence in relation to color / race, age and schooling; to analyze the number of cases of women with CCU across the country. METHODOLOGY:a bibliographic review was carried out in order to introduce, situate, conceptualize, and contextualize the CCU, prevention, diagnosis and treatment. A retrospective documentary epidemiological survey was also carried out in the State of Goiás from 2006 to 2014 through data collection in DATASUS / SISCOLO and INCA portals. RESULTS AND DISCUSSIONS:During this period, a total of 2,098,768 cervical-vaginal cytopathological exams were performed in this period, with 135,119 being normal and the remaining 1,963,649 having some alteration; of these 68,415 had precursor lesions in several stages or CCU. Demonstrates large numbers of uninformed cases showing deficiency in the preanalytic phase. CONCLUSION: the data found showed the importance of performing the Pap smear in women to prevent cervical cancer and the vaccination of children of both sexes in the age group 9 to 13 preventing the dissemination of high grade human papillomavirus agent in non - vaccinated.